JonesResearch analyst Catherine Novack downgraded Rallybio (RLYB) to Hold from Buy without a price target after the company announced discontinuation of lead asset RLYB212 in fetal and neonatal alloimmune thrombocytopenia prevention. Rallybio still has promising assets in the pipeline, but Jones needs to see Phase 1 data from early-stage assets before again recommending the shares, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLYB: